KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 96 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 1.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $363,571 | +8.3% | 37,754 | +1.2% | 0.05% | 0.0% |
| Q2 2023 | $335,754 | +14.4% | 37,306 | -0.1% | 0.05% | +15.0% |
| Q1 2023 | $293,500 | -7.7% | 37,341 | -20.6% | 0.04% | -21.6% |
| Q4 2022 | $318,017 | +128.8% | 47,044 | +233.3% | 0.05% | +325.0% |
| Q2 2022 | $139,000 | -29.8% | 14,113 | -13.5% | 0.01% | -7.7% |
| Q2 2020 | $198,000 | +33.8% | 16,325 | -15.4% | 0.01% | +8.3% |
| Q1 2020 | $148,000 | -65.3% | 19,300 | -19.4% | 0.01% | -53.8% |
| Q4 2019 | $427,000 | – | 23,952 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 422,310 | $10,849,000 | 5.86% |
| COMMODORE CAPITAL LP | 214,467 | $5,510,000 | 2.20% |
| Vivo Capital, LLC | 1,863,296 | $47,868,000 | 1.68% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 214,533 | $5,486,000 | 1.45% |
| Nicholas Investment Partners, LP | 594,130 | $15,263,000 | 1.06% |
| Altium Capital Management LP | 128,130 | $3,292,000 | 0.91% |
| Affinity Asset Advisors, LLC | 100,000 | $2,569,000 | 0.87% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,000 | $1,285,000 | 0.70% |
| APIS CAPITAL ADVISORS, LLC | 30,000 | $771,000 | 0.70% |
| Birchview Capital, LP | 40,000 | $1,028,000 | 0.61% |